CK5/6、CK14、CK17、EGFR、BRCA1、BRCA2在三阴性乳腺癌中表达的研究

The Study of CK5/6,CK14,CK17,EGFR,BRCA1,BRCA2 in the triple negative breast cancer

目的探讨CK5/6、CK14、CK17、EGFR、BRCA1、BRCA2在三阴性乳腺癌中的表达。方法采用免疫组化方法检测10例三阴性乳腺癌和15例非三阴性乳腺癌标本的CK5/6、CK14、CK17、EGFR、BRCA1、BRCA2的表达状态,并分析两组患者表达结果的差异。所有患者均经免疫组化明确ER、PR、Her-2状态。结果 10例三阴性乳腺癌患者中CK5/6阳性4例,CK14阳性4例,CK17阳性2例,EGFR阳性3例,BRCA1阳性3例,BRCA2阳性5例。三阴性与非三阴性乳腺癌在CK5/6和CK14的表达差异有显著性。将三阴性乳腺癌患者中CK5/6、CK14、CK17或EGFR有一个阳性患者分为Basal-like组,其他均为非Basal-like组,则两组患者中CK5/6、CK14、CK17的表达差异有显著性;EGFR的表达差异有显著性。结论 CK5/6和CK14在三阴性乳腺癌中高表达;CK17与EGFR在基底样细胞乳腺癌中高表达;BRCA1、BRCA2与三阴性乳腺癌关系用免疫组化方法尚难判定。

Objective T0 Study the status -of CK5/6, CK14, CKI7, EGFR, BRCA1, BRCA2 in triple negative breast cancer. Method The status of CKS/6,CK14,CK17,EGFR,BRCA1 ,BRCA2 in 10 triple negative breast cancer pa- tients and 15 non-triple negative breast cancer patients were determined by immunohistochemistry. The difference of triple and non-triple negative breast cancer was analyzed. The status of ER,PR,and HER-2 in all cases was confirmed by immunohistochemistry. Result 4 positive CK5/6,4 positive CK14,2 positive CK17,3 positive EGFR, 3 positive BRCA1,5 positive BRCA2 in 10 triple-negative breast cancer patients. The status of CK5/6 and CK14 in triple and non-triple negative breast cancer was different. The triple-negative breast cancer patients, who have one of positive status in CK5/6 ,CK14,CK17 or EGFR, were belong to Basal-like group, and the other breast cancer patients were belong to non Basal-like group. The status of CK5/6, CK14 and CK17 in the two groups was significant different, and the status of EGFR in the two groups was different in static. Condusion There are high expressions of CK5/6 and CK14 in triple negative breast cancer ; there are high expressions of CK17 and EGFR in Basal-like breast cancer ; and the statuses of BRCA1 and BRCA2 in triple negative breast cancer are not confirmed by immunohistochemistry.